Journals Library

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

This trial found that photodynamic diagnosis did not lead to a reduction in recurrence after 3 years' follow-up.

{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Rakesh Heer 1,*, Rebecca Lewis 2, Anne Duncan 3, Steven Penegar 2, Thenmalar Vadiveloo 3, Emma Clark 1, Ge Yu 1, Paramananthan Mariappan 4, Joanne Cresswell 5, John McGrath 6, James N’Dow 7, Ghulam Nabi 8, Hugh Mostafid 9, John Kelly 10, Craig Ramsay 11, Henry Lazarowicz 12, Angela Allan 13, Matthew Breckons 1, Karen Campbell 3, Louise Campbell 3, Andy Feber 10, Alison McDonald 3, John Norrie 14, Giovany Orozco-Leal 1, Stephen Rice 1, Zafer Tandogdu 10, Ernest Taylor 15, Laura Wilson 1, Luke Vale 1, Graeme MacLennan 3, Emma Hall 2

1 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
2 Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
3 Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK
4 Department of Urology, Western General Hospital, NHS Lothian, Edinburgh, UK
5 Department of Urology, South Tees Hospitals NHS Trust, Middlesbrough, UK
6 Department of Urology, Royal Devon and Exeter Hospital NHS Trust, Exeter, UK
7 Academic Urology Unit, University of Aberdeen, Aberdeen, UK
8 School of Medicine, University of Dundee, Dundee, UK
9 Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, UK
10 University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK
11 Health Services Research Unit, University of Aberdeen, Aberdeen, UK
12 Department of Urology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
13 Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK
14 Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK
15 , Tyne and Wear, UK
* Corresponding author Email: rakesh.heer@newcastle.ac.uk

Declared competing interests of authors: Rakesh Heer is a member of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Commissioning committee (2017–present). Paramananthan Mariappan reports honoraria, travel expenses, accommodation and non-financial support from Ipsen (Paris, France) and grants from Kyowa Kirin International (Galashiels, UK) outside the submitted work. Craig Ramsay is a member of HTA Board (2017–present). Henry Lazarowicz reports that urine samples from the Photodynamic versus white-light-guided resection of first diagnosis non-muscle-invasive bladder cancer–Translational (PHOTO-T) study were donated to the University of Liverpool for use in the Volatile OrganIc compounDs in bladder cancer (VOID) translational research study; the author is a co-investigator on this study and the decision to collaborate and donate samples was made independently of the author’s presence on the Trial Management Group. John Norrie reports grants from the University of Aberdeen and the University of Edinburgh during the conduct of the study, and declares membership of the following NIHR boards: the Cardiopulmonary Resuscitation (CPR) Decision-making Committee (2016), HTA Commissioning Board (2010–16), HTA Commissioning Sub-Board [Expressions of Interest (EOI)] (2012–16), HTA Funding Boards Policy Group (2016), HTA General Board (2016–19), HTA Post-Board funding teleconference (2016–19), NIHR Clinical Trials Unit (CTU) Standing Advisory Committee (2017–present), NIHRHTA and Efficacy and Mechanism Evaluation (EME) Editorial Board (2014–19) and Pre-exposure Prophylaxis Impact Review Panel (2017–present). Luke Vale reports membership of the NIHRHTA programme’s Clinical Trials and Evaluation Panel (2014–18). Emma Hall reports grants from Accuray Inc. (Sunnyvale, CA, USA), Varian Medical Systems Inc. (Crawley, UK), Merck Sharp & Dohme (Kenilworth, NJ, USA), Sanofi SA (Paris, France) and Janssen-Cilag (Beerse, Belgium); grants and non-financial support from AstraZeneca plc (Cambridge, UK); grants and non-financial support from Bayer AG (Leverkusen, Germany); and grants and non-financial support from Roche Products Ltd (Welwyn Garden City, UK) outside the submitted work.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document